Abstract C62: Identification of GSK2126458, a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR)
Steven D. Knight(GlaxoSmithKline (United States)), Dashyant Dhanak(Wilmington University), Christine Gardiner(South College), P.A. Elkins(South College), Carla A. Donatelli(South College), Michael G. Darcy(South College), Eric Garver(South College), Amita M. Chaudhari(South College), Peter J. Tummino(Intarcia Therapeutics (United States)), Stanley J. Schmidt(South College), Jeff D. Carson(GlaxoSmithKline (United States)), Joelle L. Burgess(GlaxoSmithKline (United States)), Kaushik Raha(RELX Group (Netherlands)), K. A. NEWLANDER(South College), Chiu-Mei Sung(South College), Kurt R. Auger(Research Triangle Park Foundation), Melody Diamond(South College), Glenn Van Aller(GlaxoSmithKline (United States)), Lusong Luo(BeiGene (China)), Cynthia A. Parrish(South College), Lance H. Ridgers(South College), Nicholas D. Adams(South College), Martha A. Sarpong(South College)
Cited by 4
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848